STTK Shattuck Labs, Inc.

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian cancer. It also holds a collaboration agreement with Takeda Pharmaceuticals to develop SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was founded in 2016 and is headquartered in Austin, Texas.

$28.40  +1.02 (3.73%)
As of 04/09/2021 15:59:15 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  10/08/2020
Outstanding shares:  41,775,765
Average volume:  159,874
Market cap:   $1,179,329,846
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    82024L103
ISIN:        US82024L1035
Sedol:      BM8FWT3
Valuation   (See tab for details)
PE ratio:   -30.68
PB ratio:   3.81
PS ratio:   140.70
Return on equity:   -12.42%
Net income %:   -459.19%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy